FDA Approves Ono Pharmaceutical's Romvimza for Rare Joint Tumor on February 22, 2025 Approved Cancer Therapeutic Procedure Deciphera acquisition Dosage Forms Fibrous histiocytoma of tendon sheath Infrequent Romvimza tenosynovial United States Food and Drug Administration +
FDA Approves Ono's Romvimza for Rare Joint Tumor, Challenging Daiichi Sankyo's Turalio on February 18, 2025 Approved Daiichi Dosage Forms Fibrous histiocytoma of tendon sheath Giant Cell Tumors Romvimza Sankyo tenosynovial United States Food and Drug Administration Vimseltinib +